Studies a pump with automatic insulin control in type 1 diabetes
Observes how a Control-IQ insulin pump is used by people with type 1 diabetes.
Plain-language title generated from the registry record
Registry title: The Real-World Control-IQ Glycemic Control and Quality of Life Study in Type 1 Diabetes in France
Key facts
- Where
- Agen, Angers, Bron, Dijon, Lyon, Mainvilliers, Marseille, Meaux, Metz, Montpellier, Nice, Nîmes, Palavas-les-Flots, Paris, Périgueux, Saint-Cyr-sur-Loire, Strasbourg, Toulouse, and Tours, FranceSee the 25 sites
Where in France
- CH Agen-NéracAgen, FranceTaking people
- CHU d AngersAngers, FranceTaking people
- CHU Lyon HFMEBron, FranceTaking people
- CHU DijonDijon, FranceTaking people
- Centre du Diabète - Diab-e-Care Hospices Civils de Lyon (HCL)Lyon, FranceTaking people
- Institut de Diabétologie et de Nutrition du Centre (IDNC)Mainvilliers, FranceTaking people
- Hôpital Européen (APHM)Marseille, FranceTaking people
- GHEF MeauxMeaux, FranceTaking people
- Chr Metz-ThionvilleMetz, FranceTaking people
- CHU de MontpellierMontpellier, FranceTaking people
- Clinique Saint Jean de VédasMontpellier, FranceTaking people
- Hopitaux Pediatriques de Nice CHU LenvalNice, FranceTaking people
- CHU NîmesNîmes, FranceTaking people
- Institut St-PierrePalavas-les-Flots, FranceTaking people
- GH Paris Saint-JosephParis, FranceTaking people
- Hôpital Européen Georges Pompidou APHPParis, FranceTaking people
- Hôpital LariboisièreParis, FranceTaking people
- Hopital Robert DebreParis, FranceTaking people
- Hôpital St-Antoine (APHP)Paris, FranceTaking people
- CH de PérigueuxPérigueux, FranceTaking people
- MSP Les Belles FleursSaint-Cyr-sur-Loire, FranceTaking people
- CHRU StrasbourgStrasbourg, FranceTaking people
- CHU ToulouseToulouse, FranceTaking people
- Clinique Pasteur - ToulouseToulouse, FranceTaking people
- CHU ToursTours, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tandem Diabetes Care, Inc.
- Trial code
- NCT07211126
- Record updated
- 14 October 2026
- Original description
This post-market surveillance study is primarily designed to demonstrate the ongoing safety of the Control-IQ system, the ongoing performance of glycemic control and quality of life with Control-IQ system use, and the rate of use of the Control-IQ system. The system will be assessed in all approved populations during the first 12 months of use.Read full original descriptionShow less
The Real-World Control-IQ Glycemic Control and Quality of Life Study in Type 1 Diabetes in France
This post-market surveillance study is primarily designed to demonstrate the ongoing safety of the Control-IQ system, the ongoing performance of glycemic control and quality of life with Control-IQ system use, and the rate of use of the Control-IQ system. The system will be assessed in all approved populations during the first 12 months of use.
Inclusion: Clinician-confirmed type 1 diabetes and for whom the site has initiated the t:slim X2 insulin pump with Control-IQ technology (Control-IQ System) with a Dexcom G6 or G7 CGM sensor; Age ≥ 6 years at enrollment; Using an insulin approved for use in the pump; Ability for patient or parent/guardian to respond to alerts and alarms, and to provide basic diabetes self-management; Reside full-time in mainland France; Have an email address and mobile phone number; Participant or participant's parent/guardian has read and understood the information notice and has agreed to participate in the study. This includes agreeing to :; use Control-IQ technology, and to continue use for at least 12 consecutive months after study enrollment; the reuse of their clinical data including HbA1c results, obtained at most 4 months prior to enrollment, and as available according to the standard of care during the next 12 months; complete questionnaires per the study protocol.
Exclusion: A medical or other condition, or medications being taken that, in the investigator's judgement would be a safety concern for participation in the study; Patients considered vulnerable under French law.